# EDGAR Filing Document

**Accession Number:** 0001569821
**File Stem:** 0000947871-25-000626
**Filing Date:** 2025-6
**Character Count:** 19990
**Document Hash:** 53ec14caa8407fcdccfa973359fae5d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000947871-25-000626.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0000947871-25-000626

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BiomX Inc.
- **CENTRAL INDEX KEY:** 0001739174
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823364020
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90744
- **FILM NUMBER:** 251065809

**BUSINESS ADDRESS:**
- **STREET 1:** 22 EINSTEIN ST.
- **STREET 2:** FLOOR 4
- **CITY:** NESS ZIONA
- **STATE:** L3
- **ZIP:** 7414003
- **BUSINESS PHONE:** 972 723942377

**MAIL ADDRESS:**
- **STREET 1:** 22 EINSTEIN ST.
- **STREET 2:** FLOOR 4
- **CITY:** NESS ZIONA
- **STATE:** L3
- **ZIP:** 7414003

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chardan Healthcare Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180430
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OrbiMed Israel BioFund GP Limited Partnership
- **CENTRAL INDEX KEY:** 0001569821

**ORGANIZATION NAME:**
- **EIN:** 980697985
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 46766
- **BUSINESS PHONE:** 212-739-6400

**MAIL ADDRESS:**
- **STREET 1:** 601 LEXINGTON AVENUE, 54TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 1022-4629

## Exhibit 99.1

**<u>Exhibit 1</u>**

JOINT FILING AGREEMENT

The undersigned hereby agree that the Amendment No. 6 to Schedule 13D, dated June 18, 2025, with respect to the common stock of BiomX Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 23<sup>rd</sup> day of June 2025.

---

| | |
|:---|:---|
| By: | /s/ Carl L. Gordon |
|  | Carl L. Gordon |
| By: | /s/ Erez Chimovits |
|  | Erez Chimovits |
| ORBIMED ISRAEL GP LTD. | ORBIMED ISRAEL GP LTD. |
| By: | /s/ Carl L. Gordon |
|  | Name: Carl L. Gordon |
|  | Title: Director |
| ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP | ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP |
| By: | ORBIMED ISRAEL GP LTD., its general partner |
| By: | /s/ Carl L. Gordon |
|  | Name: Carl L. Gordon |
|  | Title: Director of OrbiMed Israel GP Ltd. |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 6)**

**BiomX Inc.**

*(Name of Issuer)*

**Common stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**09090D103**

*(CUSIP Number)*

**OrbiMed Israel BioFund GP LP**<br>5 Hahoshlim St.<br>Building B, 1st Floor<br>Herzliya Pituach L3 4614001<br>972 73 2822600

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/18/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **09090D103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ORBIMED ISRAEL GP LTD.** | Name of reporting person<br>**ORBIMED ISRAEL GP LTD.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**276150.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**276150.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**276150.00** | Aggregate amount beneficially owned by each reporting person<br>**276150.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.0%** | Percent of class represented by amount in Row (11)<br>**1.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **09090D103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP** | Name of reporting person<br>**ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**276150.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**276150.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**276150.00** | Aggregate amount beneficially owned by each reporting person<br>**276150.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.0%** | Percent of class represented by amount in Row (11)<br>**1.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **09090D103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**GORDON CARL L** | Name of reporting person<br>**GORDON CARL L** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**276150.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**276150.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**276150.00** | Aggregate amount beneficially owned by each reporting person<br>**276150.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.0%** | Percent of class represented by amount in Row (11)<br>**1.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **09090D103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**CHIMOVITS EREZ** | Name of reporting person<br>**CHIMOVITS EREZ** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**276150.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**276150.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**276150.00** | Aggregate amount beneficially owned by each reporting person<br>**276150.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.0%** | Percent of class represented by amount in Row (11)<br>**1.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common stock, par value $0.0001 per share

**(b) Name of Issuer:**
BiomX Inc.

**(c) Address of Issuer's Principal Executive Offices:**
22 Einstein St., Floor 4, Ness Ziona, L3, 7414003

This Amendment No. 6 ("Amendment No. 6") to Schedule 13D supplements and amends the Statement on Schedule 13D of OrbiMed Israel GP Ltd. ("OrbiMed Israel"), OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), Carl L. Gordon ("Gordon"), and Erez Chimovits ("Chimovits") (collectively, the "Reporting Persons") originally filed with the Securities and Exchange Commission (the "SEC") on November 7, 2019 as amended by Amendment No. 1 ("Amendment No. 1") filed with the SEC on March 17, 2023, Amendment No. 2 filed with the SEC on May 8, 2023, Amendment No. 3 ("Amendment No. 3") filed with the SEC on March 8, 2024, Amendment No. 4 filed with the SEC on March 19, 2024, and Amendment No. 5 filed with the SEC on July 17, 2024. This Amendment No. 6 is being filed to report that following the transactions described in Item 5(c) below, the Reporting Persons ceased to be beneficial owners of more than 5% of the Shares and, as a result, this Amendment No. 6 is an exit filing for the Reporting Persons.

**Item 4. Purpose of Transaction**

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions.

Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in:  (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer's capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer's business or corporate structure, (g) any change in the Issuer's charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer's securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The following disclosure is based upon 26,452,461 Shares outstanding, which amounts includes 26,176,311 Shares as of May 11, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025 and gives effect to an additional 276,150 Shares issuable upon conversion of Series X Non-Voting Convertible Preferred Stock ("Series X Preferred Stock") and certain warrants to purchase Shares ("Warrants") held by the Reporting Persons.

As of the date of this filing, OIP holds an aggregate of 276,150 Shares issuable upon conversion of 223 Series X Preferred Stock and 2,538,500 Warrants. OrbiMed BioFund is the general partner of OIP pursuant to the terms of the limited partnership agreement of OIP, and OrbiMed Israel is the general partner of OrbiMed BioFund pursuant to the terms of the limited partnership agreement of OrbiMed BioFund. OrbiMed Israel exercises this investment power through an investment committee comprised of Gordon and Chimovits. As a result, OrbiMed Israel, OrbiMed BioFund, Gordon, and Chimovits share the power to direct the vote and disposition of the Shares, Series X Preferred Stock, and Warrants held by OIP, and OrbiMed Israel, OrbiMed BioFund, Gordon, and Chimovits may be deemed directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares, Series X Preferred Stock, and Warrants held by OIP.

In addition, OrbiMed Israel and OrbiMed BioFund, pursuant to their authority under the limited partnership agreement of OIP, caused OIP to enter into the agreements referred to in Item 6 below.

**(b)**
Item 5(a) is incorporated by reference herein.

**(c)**
On June 18, 2025, OIP sold 1,787,767 Shares at a price of $0.34 per Share.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed BioFund is the general partner of OIP pursuant to the terms of the limited partnership agreement of OIP. OrbiMed Israel is the general partner of OrbiMed BioFund pursuant to the terms of the limited partnership agreement of OrbiMed BioFund. Pursuant to these agreements and relationships, OrbiMed BioFund has discretionary investment management authority with respect to the assets of OIP and such discretionary investment management authority is exercised through OrbiMed Israel by action of the investment committee. Such authority includes the power to vote and otherwise dispose of securities held by OIP. The aggregate number of outstanding Shares of the Issuer attributable to OIP is 276,150, issuable upon conversion of 223 Series X Preferred Stock and 2,538,500 Warrants. OrbiMed BioFund, as the general partner of OIP, may be considered to hold 276,150 Shares issuable upon conversion of 223 Series X Preferred Stock and 2,538,500 Warrants, and OrbiMed Israel, as the general partner of OrbiMed BioFund, may be considered to hold indirectly 276,150 Shares issuable upon conversion of 223 Series X Preferred Stock and 2,538,500 Warrants.

Additionally, OIP and certain other stockholders of the Issuer are party to certain other agreements with the Issuer, summaries of which are set forth at Item 6 of Amendment No. 1 and Amendment No. 3.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ORBIMED ISRAEL GP LTD.

**Signature:** /s/ Carl L. Gordon

**Name/Title:** Carl L. Gordon/Director

**Date:** 06/23/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP

**Signature:** /s/ Carl L. Gordon

**Name/Title:** Carl L. Gordon/Director

**Date:** 06/23/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** GORDON CARL L

**Signature:** /s/ Carl L. Gordon

**Name/Title:** Carl L. Gordon

**Date:** 06/23/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** CHIMOVITS EREZ

**Signature:** /s/ Erez Chimovits

**Name/Title:** Erez Chimovits

**Date:** 06/23/2025